Symbols

WINT(Delisted)

Windtree·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About WINT

Windtree Therapeutics, Inc.

A biotech company focused on advancing multiple late-stage interventions for acute cardiovascular disorders

Industry

Established Date

Listing Date

05/20/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.windtreetx.com

Security Type

Common stock

Office address

2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976-3622

Business

Introduction

Windtree Therapeutics, Inc., was founded in Delaware in 1992. The company is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. The company's product portfolio includes istaroxime, a Phase 2 drug candidate with sarcoplasmic reticulum Ca 2 + -ATPase 2 a or SERCA 2 a that activates the properties of acute heart failure and related cardiogenic shock, preclinical SERCA 2 a activator for heart failure, rostafuroxin for the treatment of hypertension in patients with specific genetic profiles, And a preclinical atypical protein kinase C iota, or aPKCI, an inhibitor (topical and oral formulation), is being developed for potential applications in rare and broad tumor indications.

Company Financials

EPS

WINT has released its 2025 Q3 earnings. EPS was reported at -1.08, versus the expected -0.06, missing expectations. The chart below visualizes how WINT has performed over recent quarters, highlighting trends in earnings surprises.